http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-175800-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
filingDate 2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77d5c58217c181eed0f7a3189fb3141f
publicationDate 2020-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-175800-A
titleOfInvention Combination treatment of cancer
abstract The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide ), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of these combinations may be useful in the treatment of cancer. The invention also relates to pharmaceutical compositions comprising such combinations, and further relates to methods of treatment comprising the simultaneous, sequential or separate administration of AZD5363, or a pharmaceutically acceptable salt thereof, with at least one androgen receptor signalling modulator as described above, to warm-blooded animal, such as a human for the treatment of cancer. The invention also relates to a kit comprising such combinations.
priorityDate 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486648
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9821849
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419542391
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494034
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132971
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409882961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56069
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419499708
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46893585

Total number of triples: 27.